Embecta (EMBC) Projected to Post Earnings on Friday

Embecta (NASDAQ:EMBC) is expected to post its quarterly earnings results before the market opens on Friday, February 14th. Analysts expect Embecta to post earnings of $0.45 per share for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.20. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Stock Performance

NASDAQ EMBC opened at $16.62 on Thursday. The company’s 50-day simple moving average is $19.38 and its two-hundred day simple moving average is $16.57. Embecta has a one year low of $9.93 and a one year high of $21.48. The company has a market capitalization of $966.12 million, a price-to-earnings ratio of 16.62, a price-to-earnings-growth ratio of 0.95 and a beta of 1.20.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Friday, February 28th will be given a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 3.61%. The ex-dividend date is Friday, February 28th. Embecta’s payout ratio is 60.00%.

Analyst Ratings Changes

EMBC has been the topic of several analyst reports. Morgan Stanley upgraded Embecta from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $13.00 to $20.00 in a research note on Monday, December 2nd. BTIG Research upgraded shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective for the company in a research note on Wednesday, November 27th.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.